Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride

International Journal of Cancer

Volumn 76, Issue 4, 1998, Pages 519-522

  Schwartz Jr , Simó ^a,d   Caceres, Carme ^a   De Torres, Inés ^b   Morote, Joan ^b   Rodriguez Vallejo, José M ^c   Gonzalez, Jorge ^c   Reventos, Jaume ^a  

^a Ctr Investigations BBMVH   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c MERCK RESEARCH LABORATORIES   (United States)

^d BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FINASTERIDE; TESTOSTERONE;

ARTICLE; BASAL CELL; CONTROLLED STUDY; EPITHELIZATION; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

CHOLESTENONE 5 ALPHA-REDUCTASE; CULTURE TECHNIQUES; ENZYME INHIBITORS; EPITHELIUM; FINASTERIDE; GENE EXPRESSION; HUMANS; MALE; OXIDOREDUCTASES; POLYMERASE CHAIN REACTION; PROSTATIC HYPERPLASIA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA, MESSENGER; TESTOSTERONE;

EID: 2642676901     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980518)76:4<519::AID-IJC13>3.0.CO;2-2     Document Type: Article

References (32)

1. BONKHOFF, H. and REMBERGER, K., Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth - a stem cell model. Prostate, 28, 98-106 (1996).
2. BOSCH, R.J., GRIFFITHS, D.J., BLOW, J.M. and SCHROEDER, F.H., Treatment of benign prostatie hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J. Urol., 141, 68-72 (1989).
3. BOSTWICK, D.G., COONER, W.H., DENIS, L., JONKS, G.W., SCARDINO, P.T. and MURPHY, G.P., The association of benign prostatie hyperplasia and cancer of the prostate. Cancer (Suppl.), 70, 291-301 (1992).
4. BRASS, A.L., BARNARD, J., PATAL, B.L., SALVI, D. and RUKSTALIS, D.B., Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res., 55, 3197-3203 (1995).
5. CHING, K.Z., RAMSY, E., PETTIGREW, N., D'CUNHA, R., JASON, M. and DODD, J.G., Expression of mRNA for epidermal growth factor, transforming growth factor alpha and their receptor in human prostate tissue and cell lines. Mol. Cell. Biochem., 126, 151-158 (1993).
6. CHOMCZYNSKI, P. and SACCHI, N., Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159 (1987).
7. DE VITA, V.T., HELLMAN, S. and ROSENBERG, S.A., Cancer: principles and practice of oncology (3rd ed.), J.B. Lippincott, Philadelphia (1990).
8. Fox, S.B., PERSAD, R.A., COLEMAN, N., DAY, C.A., SILCOKS, P.B. and COLLINS, C.C., Prognostic value of c-erbB2 and epidermal growth factor receptor in stage A (Tla) prostatie adenocarcinoma. Br. J. Urol., 74, 214-220 (1994).
9. FRYDENBERG, M., Foo, T.M.S., JONES, A.S., GRACE, J., HKNSLEY, W.J., ROGERS, J., PEARSON, B.S. and RAGHAVAN, D., Benign prostatic hyperplasia video image analysis and its relationship to androgen and epidermal growth factor receptor expression. J. Urol., 146, 872-876 (1991).
10. FRYE, R.A., BENZ, C.C. and LIU, E., Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene, 4, 1153-1157 (1989).
11. GELLER, J., SIONIT, L., CONNORS, K., YOUNGKIN, T. and HOFFMAN, R.M., Expression of prostate-specific antigen in human prostate specimens in vitro three-dimensional histocultures. In Vitro Cell. Dev. Biol., 29A, 523-524 (1993).
12. HARPER, M.E., GODDARD, L., GLYNNEJONES, E., PEELING, W.B. and GRIFFITHS, K., Epidermal growth factor receptor expression by northern analysis and immunohistochemistry in benign and malignant prostatic tumors. Europ. J. Cancer, 31A, 1492-1497 (1995).
13. IMPERATO-MCGINLEY, J., GUERRERO, L., GAUTIER, T. and PETERSON, R.E., Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science, 186, 1213-1215 (1974).
14. KUHN, E.J., KURNOT, R.A., SESTERHENN, I.A., CHANG, E.H. and MOUL, J.W., Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J. Urol., 150, 1427-1433 (1993).
15. Liu, X.H., WILEY, H.S. and MEIKLE, A.W., Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor alpha (TGP-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J. clin. Endocrinol. Metab., 77, 1472-1478 (1993).
16. LÖNN, U., LÖNN, S., NYLÉN, U., FRIBERG, S. and STENKVIST, B., Gene amplification detected in carcinoma cells from human urinary bladder washings by the polymerase chain reaction method. Cancer, 71, 3605-3610 (1993).
17. LUBRANO, C., TOSCANO, V., PETRANGELI, E., SPERA, G., TROTTA, M.C., ROMHOLA, N., FRATI, L. DI SILVERIO, F. and SCIARRA, F., Relationship between epidermal growth factor and its receptor in human benign prostatic hyperplasia, J. Steroid. Biochem. mol. Biol., 46, 463-468 (1993).
18. MCCONNELL, J.D., WILSON, J.D., GEORGE, F.W., GELLER, J., PAPPAS, F. and STONER, E., Finasteride, an inhibitor of 5-alpha-reductase, suppresses prostatic dihydrolestosterone in men with benign prostatic hyperplasia. J. clin. Endocrinol. Metab., 74, 505-508 (1992).
19. MELLON, K., THOMPSON, S., CHARLTON, R.G., MARSH, C., ROBINSON, M., LANE, D.P., HARRIS, A.L., WILSON-HORNE, C.H. and NEAL, D.E., p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J. Urol., 147, 496-499 (1992).
20. MONTONS, K.T. and TOMASZEWSKI, J.E., In situ hybridization for epidermal growth factor receptor (EGFR) external domain transcripts in prostatic adenocarcinoma. J. clin. Lab. Anal., 7, 188-195 (1993).
21. MYERS, R.B., KUDLOW, J.E. and GRIZZLE. W.E., Expression of transforming growth factor alpha, epidermal growth factor and the epidermal growth factor receptor in adenocareinoma of the prostate and benign prostatic hyperplasia. Mod. Pathol., 6, 733-737 (1993).
22. NEVALAINEN, M.T., HARKONEN, P.L., VALVE, E.M., PING, W., NURMI, M. and MARTIKAINEN, P.M., Hormone regulation of human prostate in organ culture. Cancer Res., 53, 5199-5207 (1993).
23. NOBORI, T., MIURA, K., WU, D.J., LOIS, A., TAKABAYASHI, K. and CARSON, D.A., Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368, 753-756 (1994).
24. PEEHL, D.M., Cellular biology of prostatic growth factors. Prostate (Suppl.) 6, 74-78 (1996).
25. RITTMASTER, R.S., STONER, E., THOMPSON, D.L., NANCE, D. and LASSETER, K.C., Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J. Androl., 10, 259-262 (1989).
26. SADASIVAN, R., MORGAN, R., JENNINGS, S., AUSTENFELD, M., VAN VELDHUIZEN, P. and STEPHENS-NOBLE, M., Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J. Urol., 150, 126-131 (1993).
27. SAMBROOK, J., FRITSCH, E.F. and MANIATIS, T., Molecular cloning. A laboratory manual (2nd ed.), Vol. 2, Cold Spring Harbor Laboratory Press, New York (1989).
28. SEHGAL, I., BAILEY, J., HITZEMANN, K., PITTELKOW, M.R. and MAIHLE, N.J., Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells. Mol. Biol. Cell., 5, 339-347 (1994).
29. SHERWOOD, E.R. and LEE, C., Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J. Urol., 13, 290-296 (1995).
30. SPERA, G. and LUBRANO, C., 5-alpha-reductases and their inhibitors [Review]. Int. J. Immunopathol. Pharmacol., 9, 33-38 (1996).
31. STONER, E., 5-alpha-reductase inhibitor finasteride. Prostate (Suppl.), 6, 82-87 (1996).
32. YAMAMOTO, T., IKAWA, S., AKIYAMA, T., SEMBA, K., NOMLJRA, N., MIYAJIMA, N., SAITO, T. and TOYOSHIMA, K., Similarity protein encoded by the human c-erh-B-2 gene to epidermal growth factor receptor. Nature (Lond.), 319, 230-234 (1986).